Georgios Grammatikos, Nerea Ferreiros, Dimitra Bon, Stephanie Schwalm, Julia Dietz, Caterina Berkowski, Daniel Fitting, Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Josef Pfeilschifter – 28 October 2014 – Ablation of very‐long‐chain ceramides (Cers) with consecutive elevations in sphinganine levels has been shown to cause a severe hepatopathy in a knockout mouse model. We have recently shown that serum sphingolipids (SLs) are deregulated in patients with chronic liver disease. However, their role as possible biomarkers in liver fibrosis remains to date unexplored.

Francesco Barchiesi, Susanna Mazzocato, Sara Mazzanti, Rosaria Gesuita, Edlira Skrami, Alessandro Fiorentini, Nina Singh – 28 October 2014 – Invasive aspergillosis (IA) in liver transplant recipients is associated with grave outcomes. We reviewed 116 individual cases reported in the literature from 1985 to 2013. IA was diagnosed after a median of 25 days after transplantation and involved a single organ in 51% of the cases, whereas in the remaining cases, multiple sites were involved.

Abhisek Mitra, Arun Satelli, Jun Yan, Xia Xueqing, Mihai Gagea, Christopher A. Hunter, Lopa Mishra, Shulin Li – 28 October 2014

Joo Dong Kim, Dong Lak Choi, Young Seok Han – 28 October 2014 – Systemic heparinization has traditionally been performed during living donor hepatectomy (LDH) at most transplant centers because of the possibility of graft vascular thrombosis. However, no consensus on the use of systemic heparinization during LDH has yet emerged. The aims of the present study were to compare donor and recipient outcomes with reference to systemic heparinization and to determine whether or not systemic heparin needs to be administered to living donors.

Kendra Viner, Danica Kuncio, E. Claire Newbern, Caroline C. Johnson – 28 October 2014 – A hepatitis C virus (HCV)‐infected person will ideally have access to quality health care and move through the HCV continuum of care (CoC) from HCV antibody (Ab) screening, HCV‐RNA confirmation, engagement and retention in medical care, and treatment. Unfortunately, studies show that many patients do not progress through this continuum. Because these studies may not be generalizable, we assessed the HCV CoC in Philadelphia from January 2010 to December 2013 at the population level.

Juan G. Abraldes, Puneeta Tandon – 28 October 2014

Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld, Ningping Zhang, Qin Zhang, Fehmi Tabak, Adrian Streinu‐Cercel, Ji‐Yao Wang, Ramazan Idilman, Hendrik W. Reesink, Mircea Diculescu, Krzysztof Simon, Mihai Voiculescu, Meral Akdogan, Wlodzimierz Mazur, Jurrien G.P. Reijnders, Elke Verhey, Bettina E. Hansen, Harry L.A. Janssen, for the ARES Study Group – 28 October 2014 – Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required.

27 October 2014

Manuel Romero‐Gómez, Ángela Rojas – 25 October 2014

Dae‐Hwan Kim, Jennifer Chiyeon Rhee, Sujeong Yeo, Rongkun Shen, Soo‐Kyung Lee, Jae W. Lee, Seunghee Lee – 25 October 2014 – The histone H3‐lysine‐4 methyltransferase mixed‐lineage leukemia 3 (MLL3) and its closest homolog, MLL4 (aka KMT2D), belong to two homologous transcriptional coactivator complexes, named MLL3 and MLL4 complexes, respectively. MLL3 plays crucial roles in multiple metabolic processes. However, the physiological roles of MLL4 in metabolism and the relationship between MLL3 and MLL4 in metabolic gene regulation are unclear.